Sirtex Medical Inc. Announces Half-Year Dose Sales Report

  Sirtex Medical Inc. Announces Half-Year Dose Sales Report

            Americas Operation Achieves Continued Excellent Growth

Business Wire

WOBURN, Mass. -- March 4, 2013

Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a
leading manufacturer of targeted, innovative liver cancer therapies, announced
today that dose sales of SIR-Spheres^® microspheres in the U.S. grew more than
35 percent for the first half of the company’s fiscal year, compared to the
same period last year. Globally the company reported dose sales growth of 30.5
percent in the six months ending Dec. 31, 2012.

Sirtex attributes these gains to the increased acceptance by treating
physicians and patients of SIR-Spheres microspheres as an important option for
the treatment of colorectal cancer. SIR-Spheres microspheres are indicated for
treatment of unresectable colorectal cancer that has spread to the liver.

“This success is due to a great effort by our global team as we work to expand
awareness of our product among the global oncology community, and includes
results from our launch in Argentina,” said Mike Mangano, president of Sirtex
Medical. “Our goal is to inform and educate key medical audiences about the
role of SIR-Spheres microspheres as a treatment option to help address the
unmet need for targeted liver cancer treatments.”

Sirtex also reported that global recruitment of its flagship SIRFLOX study
passed 90 percent at the end of December and is on track to complete
recruitment of more than 500 enrolled patients by the end of March 2013. The
clinical trial is designed to obtain the data required to demonstrate that
SIR-Spheres microspheres is an effective treatment option for patients at an
earlier stage of their disease.

About Selective Internal Radiation Therapy using SIR-Spheres microspheres

Selective Internal Radiation Therapy (SIRT), also known as radioembolization,
is a proven technology for inoperable liver cancer that delivers doses of
radiation directly to the site of tumors. In a minimally invasive treatment,
millions of radioactive SIR-Spheres microspheres are infused via a catheter
into the liver where they selectively target liver tumors with a dose of
internal radiation up to 40 times higher than conventional radiotherapy, while
sparing healthy tissue.

Clinical studies have confirmed that patients with metastatic colorectal
cancer treated with SIR-Spheres microspheres have response rates higher than
with other forms of treatment, resulting in increased life expectancy, greater
periods without tumor activity and improved quality of life. SIRT has been
found to shrink liver tumors more than chemotherapy alone.

SIR-Spheres microspheres are approved for use in Australia, the United States
of America (FDA PMA approval), the European Union (CE Mark), and Argentina
(ANMAT). Additionally, SIR-Spheres microspheres are supplied in countries such
as Hong Kong, Malaysia, Singapore, Thailand, Taiwan, India, Israel, and
Turkey. Available at more than 600 treatment centers, over 25,000 doses of
SIR-Spheres microspheres have been supplied worldwide.

For more information, visit www.sirtex.com.

SIR-Spheres^® is a registered trademark of Sirtex SIR-Spheres Pty Ltd.

Contact:

Sirtex Medical Inc.
Andrea Moody, 919-457-0743
Andrea.Moody@fleishman.com
 
Press spacebar to pause and continue. Press esc to stop.